Plain English Summary
This bill revises North Carolina law regarding abortion-inducing drugs sent by mail or through remote means. It allows such drugs to be provided if a physician conducts an in-person informed consent meeting at least 72 hours beforehand, the drugs are FDA-approved, and standard informed consent requirements are met. The bill also establishes civil liability and enforcement mechanisms, including private lawsuits and potential criminal penalties.
Arguments in Favor
Supporters argue this bill protects women's health and safety by requiring in-person physician oversight before abortion-inducing drugs are provided remotely, ensuring women understand the procedure and potential risks. Proponents contend that establishing medical standards and accountability for drug suppliers protects vulnerable women and allows the state to enforce safety requirements through civil and criminal penalties.
Arguments Against
Opponents argue this bill effectively restricts access to abortion-inducing drugs by requiring in-person physician consultations, which may be impractical for women in rural areas or with limited resources. Critics contend the private right of action allowing lawsuits against patients, providers, and suppliers could chill lawful medical care and that the bill infringes on reproductive rights and medical autonomy.
AI-generated analysis based on bill text. Always verify with official sources at ncleg.gov. This is not legal or political advice.
Sponsors
Primary Sponsor
Representative · District 81
Primary Sponsor
Representative · District 117
Primary Sponsor
Representative · District 83
Primary Sponsor
Representative · District 78
Cosponsors (12)
Representative · District 5
Representative · District 53
Representative · District 111
Representative · District 26
Representative · District 59
Representative · District 109
Representative · District 52
Representative · District 69
Representative · District 84
Representative · District 70
Representative · District 67
Representative · District 96